Absolute perfection for this stock

You don’t find this often…                                                                                                                                                                                                                                                                                                                                                                                                                 April 30, 2024 | [Read Online]( Absolute perfection for this stock You don’t find this often… 📈 Join us for LIVE TRADING action all day long in the 📈  [Market Master’s Trading Room]( A week ago, the market signaled the first daily downtrend in six months. After hitting a low point on Monday last week, things have started to recover, mainly fueled by more optimism for AI and strong earnings from a couple of large tech companies. We still have a lot of news to digest this week, so get ready for a wild ride ahead! 🎢 One of the bright spots in the market lately has been biotechs. You know I am a huge fan of VKTX (a core holding of mine) and LLY, which have both been phenomenal performers. When it comes to smaller stocks in this sector, we have already seen some amazing moves on the year.  I’ve already alerted you to some smaller biotechs that have moved 100% (or more) in a matter of days. Today, I have an incredible new idea to share with you. Pull up Cardiol Therapeutics Inc. (CRDL) on your platform right now, and let’s dig in… Below, I posted a chart showing the daily action for nearly a year. I want you to look at this chart so you can really get a perspective on the overwhelming bullish trend in place for this stock right now. You will be hard-pressed to find a stock with the remarkable strength that we have seen for CRDL over the last several months. In fact, you’ll notice that even with all of the market “chop,” CRDL has managed to more than double its price so far this year. And I don’t see any reason to think that is over. I highlighted two areas on the chart above, both showing what I call a “wedge pattern.” Those are times when the trading range becomes extremely tight, and it is usually followed by a significant move. When you have a rising wedge (like we see above), the breakout to the upside can be significant. These moves can happen very quickly, so it is important to prepare and have a plan in place. If you see the last time CRDL broke out of this wedge, it gained over 50% in just a few days. I absolutely love this pattern. There are not many opportunities like this in the market right now, so make sure you are keeping a close eye on CRDL. I don’t think you need to be a technical trading expert to see the strong trend in place over the last several months, but if you want another opinion, look at what [Barchart]( has to say about CRDL right now… Their technical rating tool pegs CRDL with a pristine “100% BUY” right now. It’s impossible to get any better than that. As I said, this is a rare find, especially considering the market conditions we have at the moment. Do not let this one slip away from you! Company Overview Cardiol Therapeutics Inc. (CRDL) is a clinical-stage life sciences company developing cannabidiol-based products to treat heart diseases. In the wake of Covid, pericarditis and myocarditis have become household names. Most people now know that these are inflammatory heart conditions that can significantly impact quality of life — and sometimes even prove fatal. What they don’t know is that these conditions have very few effective treatments. Partnering with healthcare heavyweights such as the Mayo Clinic and Cleveland Clinic, Toronto-based CRDL is working to address these significant unmet needs. Importantly, many studies have shown that cannabidiol (better known as CBD) can inhibit multiple inflammatory pathways that are activated, particularly in cases of pericarditis and myocarditis. The Company’s lead drug candidate is a novel prescription-strength cannabidiol product named CardiolRx™ that has already been granted FDA [orphan drug designation]( (ODD) for treatment of pericarditis, and it is eligible for ODD for treatment of acute myocarditis. CardiolRx™ has already progressed into two Phase II trials: the MAvERIC-Pilot study for the treatment of recurrent pericarditis (RP), and the ARCHER trial for the treatment of acute myocarditis (AM). The MAvERIC-Pilot study is chaired by Dr. Allan Klein, who is also the director of the Center for the Diagnosis and Treatment of Pericardial Diseases at the Cleveland Clinic, one of the largest pericardial disease centers in the world. CRDL picked the right man for the job. Dr. Klein was also the principal investigator for the Phase III trial of the first FDA-approved drug — Arcalyst — with an indication specifically for RP. Not only does Arcalyst have an extraordinary price tag of $270,000 per patient per year, the drug can also suppress the immune system, potentially causing serious infections. Nevertheless, despite debuting recently in 2021, Arcalyst brought in $233.2 million in 2023, and it’s expected to bring in $360–380 million this year. Clearly, this market is ripe for competition. CRDL [achieved 100% enrollment]( in the MAvERIC-Pilot study in February and expects topline results this quarter. Significantly, clinical development of Arcalyst proceeded on an accelerated 3-year timeline, and CRDL appears to be using the Arcalyst trials as a template for its own. Their other Phase II trial — ARCHER — is chaired by Dr. Dennis McNamara, director of the heart failure/transplantation program at the University of Pittsburgh Medical Center, and the co-chair is Dr. Leslie Cooper, Jr., who is also chair of the Mayo Clinic Enterprise Department of Cardiovascular Medicine. Right now, there are no FDA-approved therapies for acute myocarditis, so there is a major unmet need here – there are an estimated 46,000 AM cases each year in the US. The trial [recently exceeded]( 50% enrollment, and CRDL expects to reach full enrollment in Q3, ahead of the expected schedule. CRDL has [reported]( $34.9 million in cash and cash equivalents as of December 31, 2023, giving it a cash runway that it expects will fund operations into 2026. Spend time right now doing your own research on the stock, and of course, always approach your trading in a responsible manner. Trading is very risky, and nothing is ever guaranteed, so never trade with more than you can afford to lose. Always have a well-thought-out game plan that takes your personal risk tolerance into consideration. Bottom line: This is one of the best trading setups I have seen in a long time. With perfect “100% BUY” signals flashing, CRDL seems like a no-brainer to me to watch right now. This stock should be on the very top of your watchlist as we wait to see which direction the next breakout will take it. To Your Success, Jeff Bishop 👊 Make sure you are getting my mobile text alerts –  text “RAGE” to 1-(888) 404-5747 to get all of my latest HOT STOCK ideas delivered right to your phone (make sure you put the “1” at the front!). Don’t miss out! If you have trouble reading anything in this email, [please visit here](. [tw]( Update your email preferences or unsubscribe [here]( © 2024 Bullseye Trades 62 Calef Hwy. #233 Lee, NH 03861, United States of America